Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL

References

• Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–12. doi:10.1056/NEJMoa1407222.
   PubMed Web of Science ®Google Scholar
• Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in Acute Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):449–459. doi:10.1056/NEJMoa1709919.
   PubMed Web of Science ®Google Scholar
• Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69 (2021). doi:10.1038/s41408-021-00459-7.
   PubMed Web of Science ®Google Scholar
• Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372–385. doi:10.1038/s41571-019-0184-6.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866.
   PubMed Web of Science ®Google Scholar
• Xu X, Sun Q, Liang X, Chen Z, Zhang X, Zhou X, Li M, Tu H, Liu Y, Tu S et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute Lymphoblastic Leukemia and its prevention and treatment Strategies. Front Immunol. 2019;10:2664. doi:10.3389/fimmu.2019.02664.
   PubMed Web of Science ®Google Scholar
• Guo Z, Tu S, Yu S, Wu L, Pan W, Chang N, Zhou X, Song C, Li Y, He Y, et al. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Cancer Sci 2021;01(9ed2021):1357–1368. doi:10.1111/cas.14799.
   Google Scholar
• Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–28. doi:10.1038/nm.4441.
   PubMed Web of Science ®Google Scholar
• Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27(8):1419–1431. doi:10.1038/s41591-021-01436-0.
   PubMed Web of Science ®Google Scholar
• Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569–1575. doi:10.1038/s41591-020-1081-3.
   PubMed Web of Science ®Google Scholar
• Larson SMW, Ji CM, Ghafouri B, Naparstek SN, Trent, J J. CD19/CD20 bispecific chimeric antigen receptor (CAR) in naïve/memory T cells for the treatment of relapsed or refractory non-hodgkin lymphoma. Cancer Discov. 2022;13:1–18. doi:10.1158/2159-8290.CD-22-0964.
   Google Scholar
• Orlando EJ, Han X, Tribouley C, Wood PA, Leary RJ, Riester M, Levine JE, Qayed M, Grupp SA, Boyer M, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24(10):1504–1506. doi:10.1038/s41591-018-0146-z.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282–1295. doi:10.1158/2159-8290.CD-15-1020.
   PubMed Web of Science ®Google Scholar
• Asnani M, Hayer KE, Naqvi AS, Zheng S, Yang SY, Oldridge D, Ibrahim F, Maragkakis M, Gazzara MR, Black KL, et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia. 2020;34(4):1202–1207. doi:10.1038/s41375-019-0580-z.
   PubMed Web of Science ®Google Scholar
• Bagashev A, Sotillo E, Tang CH, Black KL, Perazzelli J, Seeholzer SH, Argon Y, Barrett DM, Grupp SA, Hu CC, et al. CD19 alterations emerging after CD19-directed immunotherapy cause retention of the Misfolded protein in the endoplasmic reticulum. Mol Cell Biol. 2018;38(21):21. doi:10.1128/MCB.00383-18.
   Web of Science ®Google Scholar
• Rabilloud T, Potier D, Pankaew S, Nozais M, Loosveld M, Payet-Bornet D. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat Commun. 2021;12:865.
   PubMed Web of Science ®Google Scholar
• Fischer J, Paret C, El Malki K, Alt F, Wingerter A, Neu MA, Kron B, Russo A, Lehmann N, Roth L, et al. CD19 Isoforms enabling Resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis. J Immunother. 2017;40(5):187–195. doi:10.1097/CJI.0000000000000169.
   PubMed Web of Science ®Google Scholar
• Cortés-López M, Schulz L, Enculescu M, Paret C, Spiekermann B, Quesnel-Vallières M, Torres-Diz M, Unic S, Busch A, Orekhova A, et al. High-throughput mutagenesis identifies mutations and RNA-binding proteins controlling CD19 splicing and CART-19 therapy resistance. Nat Commun. 2022;13(1). doi:10.1038/s41467-022-31818-y.
   PubMed Web of Science ®Google Scholar
• Giudice G, Sanchez-Cabo F, Torroja C, Lara-Pezzi E. ATtRACT-a database of RNA-binding proteins and associated motifs. Database (Oxford). 2016;2016:baw035. doi:10.1093/database/baw035.
   PubMedGoogle Scholar
• Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, Mesirov JP. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24–26. doi:10.1038/nbt.1754.
   PubMed Web of Science ®Google Scholar
• McLeod C, Gout AM, Zhou X, Thrasher A, Rahbarinia D, Brady SW, Macias M, Birch K, Finkelstein D, Sunny J, et al. St. jude cloud: a pediatric cancer genomic data-sharing ecosystem. Cancer Discov. 2021;11(5):1082–1099. doi:10.1158/2159-8290.CD-20-1230.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8.
   PubMed Web of Science ®Google Scholar
• Stephens M. False discovery rates: a new deal. Biostatistics. 2017;18(2):275–294. doi:10.1093/biostatistics/kxw041.
   PubMed Web of Science ®Google Scholar
• Perez I, Lin CH, McAfee JG, Patton JG. Mutation of PTB binding sites causes misregulation of alternative 3’ splice site selection in vivo. RNA. 1997;3:764–778.
   PubMed Web of Science ®Google Scholar
• Feng H, Bao S, Rahman MA, Weyn-Vanhentenryck SM, Khan A, Wong J, Shah A, Flynn ED, Krainer AR, Zhang C, et al. Modeling RNA-binding protein specificity in vivo by precisely registering protein-RNA crosslink sites. Mol Cell. 2019;74(6):1189–204 e6. doi:10.1016/j.molcel.2019.02.002.
   PubMed Web of Science ®Google Scholar
• Dominguez D, Freese P, Alexis MS, Su A, Hochman M, Palden T, Bazile C, Lambert NJ, Van Nostrand EL, Pratt GA, et al. Sequence, structure, and context preferences of human RNA binding proteins. Mol Cell. 2018;06(9ed2018):854–67 e9. doi:10.1016/j.molcel.2018.05.001.
   Google Scholar
• Han A, Stoilov P, Linares AJ, Zhou Y, Fu XD, Black DL, Guigo R. De novo prediction of PTBP1 binding and splicing targets reveals unexpected features of its RNA recognition and function. PLoS Comput Biol. 2014;10(1):e1003442. doi:10.1371/journal.pcbi.1003442.
   PubMed Web of Science ®Google Scholar
• Amir-Ahmady B, Boutz PL, Markovtsov V, Phillips ML, Black DL. Exon repression by polypyrimidine tract binding protein. RNA. 2005;11(5):699–716. doi:10.1261/rna.2250405.
   PubMed Web of Science ®Google Scholar
• Mukherjee N, Jacobs NC, Hafner M, Kennington EA, Nusbaum JD, Tuschl T, Blackshear PJ, Ohler U. Global target mRNA specification and regulation by the RNA-binding protein ZFP36. Genome Biol. 2014;15(1):R12. doi:10.1186/gb-2014-15-1-r12.
   PubMed Web of Science ®Google Scholar
• Spellman R, Llorian M, Smith CW. Crossregulation and functional redundancy between the splicing regulator PTB and its paralogs nPTB and ROD1. Mol Cell. 2007;27(3):420–434. doi:10.1016/j.molcel.2007.06.016.
   PubMed Web of Science ®Google Scholar
• Jung H, Lee D, Lee J, Park D, Kim YJ, Park WY, Hong D, Park PJ, Lee E. Intron retention is a widespread mechanism of tumor-suppressor inactivation. Nat Genet. 2015;47(11):1242–1248. doi:10.1038/ng.3414.
   PubMed Web of Science ®Google Scholar
• Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B. Synonymous mutations frequently act as driver mutations in human cancers. Cell. 2014;156(6):1324–1335. doi:10.1016/j.cell.2014.01.051.
   PubMed Web of Science ®Google Scholar
• Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, Bailey SL, Bhavsar EB, Chan B, Colla S, et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3’ splice site selection through use of a different branch point. Cell Rep. 2015;13(5):1033–1045. doi:10.1016/j.celrep.2015.09.053.
   PubMed Web of Science ®Google Scholar
• Quesada V, Conde L, Villamor N, Ordonez GR, Jares P, Bassaganyas L, Ramsay AJ, Beà S, Pinyol M, Martínez-Trillos A, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet. 2011;44(1):47–52. doi:10.1038/ng.1032.
   PubMed Web of Science ®Google Scholar
• Climente-Gonzalez H, Porta-Pardo E, Godzik A, Eyras E. The functional impact of alternative splicing in cancer. Cell Rep. 2017;20(9):2215–2226. doi:10.1016/j.celrep.2017.08.012.
   PubMed Web of Science ®Google Scholar
• Peng Q, Zhou Y, Oyang L, Wu N, Tang Y, Su M, Luo X, Wang Y, Sheng X, Ma J, et al. Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics. Mol Ther. 2021;11:19ed2021.
   Google Scholar
• Oberstrass FC, Auweter SD, Erat M, Hargous Y, Henning A, Wenter P, Reymond L, Amir-Ahmady B, Pitsch S, Black DL, et al. Structure of PTB bound to RNA: specific binding and implications for splicing regulation. Science. 2005;309(5743):2054–2057. doi:10.1126/science.1114066.
   PubMed Web of Science ®Google Scholar
• Galloway A, Saveliev A, Lukasiak S, Hodson DJ, Bolland D, Balmanno K, Ahlfors H, Monzón-Casanova E, Mannurita SC, Bell LS, et al. RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence. Science. 2016;352(6284):453–459. doi:10.1126/science.aad5978.
   PubMed Web of Science ®Google Scholar
• Zekavati A, Nasir A, Alcaraz A, Aldrovandi M, Marsh P, Norton JD, Murphy JJ. Post-transcriptional regulation of BCL2 mRNA by the RNA-binding protein ZFP36L1 in malignant B cells. PLoS One. 2014;9(7):e102625. doi:10.1371/journal.pone.0102625.
   PubMed Web of Science ®Google Scholar
• Newman R, Ahlfors H, Saveliev A, Galloway A, Hodson DJ, Williams R, Besra GS, Cook CN, Cunningham AF, Bell SE, et al. Maintenance of the marginal-zone B cell compartment specifically requires the RNA-binding protein ZFP36L1. Nat Immunol. 2017;18(6):683–693. doi:10.1038/ni.3724.
   PubMed Web of Science ®Google Scholar
• Monzon-Casanova E, Matheson LS, Tabbada K, Zarnack K, Smith CW, Turner M. Polypyrimidine tract-binding proteins are essential for B cell development. Elife. 2020;9. doi:10.7554/eLife.53557.
   PubMed Web of Science ®Google Scholar
• Monzon-Casanova E, Screen M, Diaz-Munoz MD, Coulson RMR, Bell SE, Lamers G, Solimena M, Smith CWJ, Turner M. The RNA-binding protein PTBP1 is necessary for B cell selection in germinal centers. Nat Immunol. 2018;19(3):267–278. doi:10.1038/s41590-017-0035-5.
   PubMed Web of Science ®Google Scholar
• Black KL, Naqvi AS, Asnani M, Hayer KE, Yang SY, Gillespie E, Bagashev A, Pillai V, Tasian SK, Gazzara MR, et al. Aberrant splicing in B-cell acute lymphoblastic leukemia. Nucleic Acids Res. 2018;46(21):11357–11369. doi:10.1093/nar/gky946.
   PubMed Web of Science ®Google Scholar
• Xiao W, Adhikari S, Dahal U, Chen YS, Hao YJ, Sun BF, Sun H-Y, Li A, Ping X-L, Lai W-Y, et al. Nuclear m(6)A Reader YTHDC1 Regulates mRNA Splicing. Mol Cell. 2016;61(4):507–519. doi:10.1016/j.molcel.2016.01.012.
   PubMed Web of Science ®Google Scholar
• Katsuyama T, Moulton VR. Splicing factor SRSF1 is indispensable for regulatory T cell homeostasis and function. Cell Rep. 2021;36(1):109339. doi:10.1016/j.celrep.2021.109339.
   PubMed Web of Science ®Google Scholar
• Diaz-Munoz MD, Osma-Garcia IC. The RNA regulatory programs that govern lymphocyte development and function. Wiley Interdiscip Rev RNA. 2021;13(1):e1683. doi:10.1002/wrna.1683.
   PubMed Web of Science ®Google Scholar
• Diaz-Munoz MD, Turner M. Uncovering the role of RNA-binding proteins in gene expression in the immune system. Front Immunol. 2018;9:1094. doi:10.3389/fimmu.2018.01094.
   PubMed Web of Science ®Google Scholar
• Turner M, Diaz-Munoz MD. RNA-binding proteins control gene expression and cell fate in the immune system. Nat Immunol. 2018;01(20ed2018):120–129. doi:10.1038/s41590-017-0028-4.
   Google Scholar
• Keene JD. RNA regulons: coordination of post-transcriptional events. Nat Rev Genet. 2007;8(7):533–543. doi:10.1038/nrg2111.
   PubMed Web of Science ®Google Scholar
• Guo J, Jia J, Jia R. PTBP1 and PTBP2 impaired autoregulation of SRSF3 in cancer cells. Sci Rep. 2015;5(1):14548. doi:10.1038/srep14548.
   PubMedGoogle Scholar
• Zhou Z, Gong Q, Lin Z, Wang Y, Li M, Wang L, Ding H, Li P. Emerging Roles of SRSF3 as a Therapeutic Target for Cancer. Front Oncol. 2020;10:577636. doi:10.3389/fonc.2020.577636.
   PubMed Web of Science ®Google Scholar
• Izquierdo JM, Majos N, Bonnal S, Martinez C, Castelo R, Guigo R, Bilbao D, Valcárcel J. Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon definition. Mol Cell. 2005;19(4):475–484. doi:10.1016/j.molcel.2005.06.015.
   PubMed Web of Science ®Google Scholar
• Downing JR, Wilson RK, Zhang J, Mardis ER, CH P, Ding L, Ley TJ, Evans WE. The Pediatric Cancer Genome Project. Nat Genet. 2012;44(6):619–622. doi:10.1038/ng.2287.
   PubMed Web of Science ®Google Scholar
• Newman S, Nakitandwe J, Kesserwan CA, Azzato EM, Wheeler DA, Rusch M, Shurtleff S, Hedges DJ, Hamilton KV, Foy SG, et al. Genomes for kids: the scope of pathogenic mutations in pediatric cancer revealed by comprehensive DNA and RNA sequencing. Cancer Discov. 2021;11(12):3008–3027. doi:10.1158/2159-8290.CD-20-1631.
   PubMed Web of Science ®Google Scholar
• Rusch M, Nakitandwe J, Shurtleff S, Newman S, Zhang Z, Edmonson MN, Parker M, Jiao Y, Ma X, Liu Y, et al. Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat Commun. 2018;9(1):3962. doi:10.1038/s41467-018-06485-7.
   PubMedGoogle Scholar
• Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562(7727):373–379. doi:10.1038/s41586-018-0436-0.
   PubMed Web of Science ®Google Scholar
• Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, Nakitandwe J, Holmfeldt L, Parker M, Easton J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47(4):330–337. doi:10.1038/ng.3230.
   PubMed Web of Science ®Google Scholar
• Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296–307. doi:10.1038/s41588-018-0315-5.
   PubMed Web of Science ®Google Scholar
• Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014;371(11):1005–1015. doi:10.1056/NEJMoa1403088.
   PubMed Web of Science ®Google Scholar